查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1908646

乳癌药物市场规模、份额和趋势分析报告：按治疗方法、癌症类型、分销管道、地区和细分市场预测（2025-2033 年）

Breast Cancer Drugs Market Size, Share & Trends Analysis Report By Therapy (Hormonal Therapy, Targeted Therapy, Chemotherapy, Immunotherapy), By Cancer Type, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

乳癌药物市场概况

2024年全球乳癌治疗市场规模估计为366.2亿美元，预计2033年将达到697.2亿美元。

预计从 2025 年到 2033 年，该市场将以 7.09% 的复合年增长率成长。推动市场成长的几个关键因素包括全球乳癌发生率的上升、诊断技术的进步以及个人化医疗的日益普及。

根据美国癌症协会2025年5月发布的数据，美国将有约316,950名女性被诊断出罹患乳癌，这反映出对新型治疗方法的巨大需求。透过基因检测（例如BRCA基因突变检测）和改进的筛检方法，早期发现乳癌成为可能，有助于更早诊断，并制定有效的治疗策略。针对HER2和荷尔蒙受体的个人化疗法在治疗领域的重要性日益凸显。此外，精准医疗（包括生物标记指导治疗和免疫疗法）的广泛应用正在塑造乳癌治疗的未来，并成为市场扩张的主要驱动力。

目前市场正从传统化疗转向更具标靶性、毒性较小的治疗方法，例如单株抗体、荷尔蒙受体标靶治疗和免疫疗法。 Kadcyla（ado-trastuzumab emtansine）和Trodelvy（sacituzumab govitecan）等治疗方法已引起广泛关注，尤其是在乳癌阳性乳癌和三阴性乳癌的治疗方面。与传统化疗方案相比，这些治疗方法展现出更高的疗效和更少的副作用。 Keytruda（ Pembrolizumab ）是一种免疫疗法，目前正在与其他治疗方法联合研究，在HER2阴性乳癌的治疗中显示出良好的前景。这种对先进治疗方法的日益依赖正在重塑治疗模式，尤其强调联合治疗，预计这将有助于改善患者的治疗效果。

乳癌治疗市场业务发展迅速，合作计画众多，研发管线不断推进。截至2025年8月，已有超过300种药物正在研发中，包括抗体药物复合体（ADC）、小分子药物和具有全新作用机制的蛋白水解靶向嵌合体（PROTAC）。辉瑞公司于2025年4月宣布，将乳癌数据（包括针对ER阳性/HER2阴性转移性乳癌的III期临床试验「VERITAC-2」）纳入其肿瘤产品组合，重点在于推进新一代抗体偶联物（ADC）与免疫查核点抑制剂联合疗法的研发。 2024年4月，美国食品药物管理局（FDA）核准了赫赛汀（曲妥珠单抗）的生物相似药HERCESSI（曲妥珠单抗-strf），用于治疗HER2过度表现的乳癌以及胃癌或胃食道交界处腺癌。预计这将提高患者获得这种重要治疗的机会，同时降低治疗成本。这些合作和新药的上市显示市场正在不断发展，各大製药公司都在寻求加强其产品组合併拓展治疗选择，尤其是在HER2低表达和三阴性乳癌等复杂亚型方面。

目录

第一章调查方法和范围

第二章执行摘要

第三章乳癌药物市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章乳癌治疗药物市场：依治疗方法的业务分析

  • 按治疗方法的市场份额（2024 年和 2033 年）
  • 按治疗方法的市场规模、预测和趋势分析（2021-2033 年）
  • 荷尔蒙疗法
  • 标靶治疗
  • 化疗
  • 免疫疗法

第五章乳癌药物市场：按癌症类型分類的业务分析

  • 按癌症类型分類的市场份额（2024 年和 2033 年）
  • 市场规模、预测与趋势分析：按癌症类型划分（2021-2033 年）
  • HR+/HER2-乳癌
  • HER2阳性乳癌
  • 三阴性乳癌（TNBC/HR-/HER2-）

第六章乳癌药物市场：按分销管道分類的业务分析

  • 按分销管道分類的市场份额（2024 年和 2033 年）
  • 按分销管道分類的市场规模、预测和趋势分析（2021-2033 年）
  • 医院药房
  • 零售药房
  • 其他的

第七章乳癌药物市场：区域估算与趋势分析

  • 区域市场占有率分析（2024 年和 2033 年）
  • 区域市场概览
  • 市场规模及预测趋势分析（2021-2033）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争情势

  • 参与公司概况
  • 企业市场分析
  • 公司分类
  • 策略规划
  • 公司简介/列表
    • Pfizer Inc.
    • AbbVie Inc.
    • F. Hoffmann-La Roche Ltd.
    • AstraZeneca PLC
    • Novartis AG
    • Eli Lilly &Company
    • Sanofi SA
    • Merck &Co., Inc.
    • Bristol-Myers Squibb Company
    • Eisai Co., Ltd.
    • MacroGenics
    • Biocon Genzyme
    • Takeda Pharmaceutical Co., LTD.
    • Kyowa Kirin Co., Ltd.
    • Janssen Global Services LLC
Product Code: GVR-3-68038-041-5

Breast Cancer Drugs Market Summary

The global breast cancer drugs market size was estimated at USD 36.62 billion in 2024 and is projected to reach USD 69.72 billion by 2033, growing at a CAGR of 7.09% from 2025 to 2033. The market is driven by several critical factors, including the increasing global incidence of breast cancer, advancements in diagnostic technologies, and a growing shift toward personalized medicine.

According to the American Cancer Society's published data in May 2025, around 316,950 women in the United States will be diagnosed with breast cancer, which reflects a significant demand for novel therapies. The focus on early detection, facilitated by improved screening methods and genetic testing such as BRCA mutation testing, has led to earlier diagnoses, allowing for more effective treatment strategies. Personalized therapies, particularly those targeting HER2 and hormone receptors, are becoming increasingly vital in the treatment landscape. Moreover, the growing use of precision medicine, including biomarker-driven treatments and immunotherapies, is helping to shape the future of breast cancer care, making it a key driver of market expansion.

The current market is marked by a shift away from traditional chemotherapy toward more targeted and less toxic treatments, such as monoclonal antibodies, hormone receptor-targeted therapies, and immunotherapies. Also, therapies like Kadcyla (ado-trastuzumab emtansine) and Trodelvy (sacituzumab govitecan) have gained significant traction, particularly for treating HER2-positive and triple-negative breast cancer, respectively. These therapies have demonstrated greater efficacy and fewer side effects compared to traditional chemotherapy regimens. Keytruda (pembrolizumab), an immunotherapy currently being studied in combination with other treatments, shows promise in treating HER2-negative breast cancer. This growing reliance on more advanced therapies is reshaping treatment paradigms, with a strong emphasis on combination therapies that are expected to enhance patient outcomes.

Business development within the breast cancer drugs market is also expanding rapidly, with numerous collaborations and advancements in the pipeline. By August 2025, over 300 drugs were under development, including antibody-drug conjugates (ADCs), small molecules, and novel mechanisms like proteolysis-targeting chimeras (PROTACs). According to Pfizer Inc., in April 2025, the company announced that its oncology portfolio will include data presentations in breast cancer - including a Phase 3 study (VERITAC-2) in ER+/HER2- metastatic breast cancer - and emphasized the development of next-generation antibody-drug conjugates (ADCs) in combination with immune checkpoint inhibitors. In April2024, the HERCESSI (trastuzumab-strf) biosimilar to Herceptin(trastuzumab) was approved by the U.S. Food & Drug Administration (FDA) for the treatment of HER2-overexpressing breast cancer and gastric or gastroesophageal junction adenocarcinoma., is expected to drive down costs while improving access to critical treatments. These collaborations and new drug introductions highlight the ongoing evolution of the market, with major pharmaceutical companies looking to enhance their portfolios and broaden treatment options, especially for complex subtypes like HER2-low and triple-negative breast cancer.

Global Breast Cancer Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global breast cancer drugs market report based on therapy, cancer type, distribution channel, and region:

  • Therapy Outlook (Revenue, USD Million, 2021 - 2033)
  • Hormonal Therapy
    • Selective Estrogen Receptor Modulators (SERMs)
    • Aromatase Inhibitors
    • Selective Estrogen Receptor Degraders/Down-regulators (SERDs)
  • Targeted Therapy
    • HER2-Targeted Therapies
    • CDK4/6 Inhibitors
    • PARP Inhibitors
    • Antibody-Drug Conjugates (ADCs)
    • Other Targeted Therapies
  • Chemotherapy
    • Taxanes
    • Anthracyclines
    • Others
  • Immunotherapy
  • Cancer Type Outlook (Revenue, USD Million, 2021 - 2033)
  • HR+/HER2- Breast Cancer
  • HER2+ Breast Cancer
  • Triple-Negative Breast Cancer (TNBC / HR-/HER2-)
  • Distribution ChannelOutlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Therapy
    • 1.2.2. Cancer Type
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Breast Cancer Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Breast Cancer Drugs Market: Therapy Business Analysis

  • 4.1. Therapy Market Share, 2024 & 2033
  • 4.2. Therapy Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Therapy, 2021 to 2033 (USD Million)
  • 4.4. Hormonal Therapy
    • 4.4.1. Hormonal Therapy Market, 2021 - 2033 (USD Million)
    • 4.4.2. Selective Estrogen Receptor Modulators (SERMs)
      • 4.4.2.1. Selective Estrogen Receptor Modulators (SERMs) Market, 2021 - 2033 (USD Million)
    • 4.4.3. Aromatase Inhibitors
      • 4.4.3.1. Aromatase Inhibitors Market, 2021 - 2033 (USD Million)
    • 4.4.4. Selective Estrogen Receptor Degraders/Down-regulators (SERDs)
      • 4.4.4.1. Selective Estrogen Receptor Degraders/Down-regulators (SERDs) Market, 2021 - 2033 (USD Million)
  • 4.5. Targeted Therapy
    • 4.5.1. Targeted Therapy Market, 2021 - 2033 (USD Million)
    • 4.5.2. HER2-Targeted Therapies
      • 4.5.2.1. HER2-Targeted Therapies Market, 2021 - 2033 (USD Million)
    • 4.5.3. CDK4/6 Inhibitors
      • 4.5.3.1. CDK4/6 Inhibitors Market, 2021 - 2033 (USD Million)
    • 4.5.4. PARP Inhibitors
      • 4.5.4.1. PARP Inhibitors Market, 2021 - 2033 (USD Million)
    • 4.5.5. Antibody-Drug Conjugates (ADCs)
      • 4.5.5.1. Antibody-Drug Conjugates (ADCs) Market, 2021 - 2033 (USD Million)
    • 4.5.6. Other Targeted Therapies
      • 4.5.6.1. Other Targeted Therapies Market, 2021 - 2033 (USD Million)
  • 4.6. Chemotherapy
    • 4.6.1. Chemotherapy Market, 2021 - 2033 (USD Million)
    • 4.6.2. Taxanes
      • 4.6.2.1. Taxanes Market, 2021 - 2033 (USD Million)
    • 4.6.3. Anthracyclines
      • 4.6.3.1. Anthracyclines Market, 2021 - 2033 (USD Million)
    • 4.6.4. Others
      • 4.6.4.1. Others Market, 2021 - 2033 (USD Million)
  • 4.7. Immunotherapy
    • 4.7.1. Immunotherapy Market, 2021 - 2033 (USD Million)

Chapter 5. Breast Cancer Drugs Market: Cancer Type Business Analysis

  • 5.1. Cancer Type Market Share, 2024 & 2033
  • 5.2. Cancer Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Cancer Type, 2021 to 2033 (USD Million)
  • 5.4. HR+/HER2- Breast Cancer
    • 5.4.1. HR+/HER2- Breast Cancer Market, 2021 - 2033 (USD Million)
  • 5.5. HER2+ Breast Cancer
    • 5.5.1. HER2+ Breast Cancer Market, 2021 - 2033 (USD Million)
  • 5.6. Triple-Negative Breast Cancer (TNBC / HR-/HER2-)
    • 5.6.1. Triple-Negative Breast Cancer (TNBC / HR-/HER2-) Market, 2021 - 2033 (USD Million)

Chapter 6. Breast Cancer Drugs Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2033
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Breast Cancer Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
  • 7.4. North America
    • 7.4.1. North America Breast Cancer Drugs Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Breast Cancer Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. U.S. Breast Cancer Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Breast Cancer Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Breast Cancer Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. Uk Breast Cancer Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Breast Cancer Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Breast Cancer Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Breast Cancer Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Breast Cancer Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Breast Cancer Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Breast Cancer Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Breast Cancer Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Breast Cancer Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Breast Cancer Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Breast Cancer Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Breast Cancer Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Breast Cancer Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Breast Cancer Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Breast Cancer Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Breast Cancer Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Japan Breast Cancer Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. China Breast Cancer Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Breast Cancer Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Breast Cancer Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Breast Cancer Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Breast Cancer Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Breast Cancer Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Pfizer Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. AbbVie Inc.
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. F. Hoffmann-La Roche Ltd.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. AstraZeneca PLC
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Novartis AG
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Eli Lilly & Company
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Sanofi S.A.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Merck & Co., Inc.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Bristol-Myers Squibb Company
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Eisai Co., Ltd.
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. MacroGenics
      • 8.5.11.1. Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic Initiatives
    • 8.5.12. Biocon Genzyme
      • 8.5.12.1. Overview
      • 8.5.12.2. Financial Performance
      • 8.5.12.3. Product Benchmarking
      • 8.5.12.4. Strategic Initiatives
    • 8.5.13. Takeda Pharmaceutical Co., LTD.
      • 8.5.13.1. Overview
      • 8.5.13.2. Financial Performance
      • 8.5.13.3. Product Benchmarking
      • 8.5.13.4. Strategic Initiatives
    • 8.5.14. Kyowa Kirin Co., Ltd.
      • 8.5.14.1. Overview
      • 8.5.14.2. Financial Performance
      • 8.5.14.3. Product Benchmarking
      • 8.5.14.4. Strategic Initiatives
    • 8.5.15. Janssen Global Services LLC
      • 8.5.15.1. Overview
      • 8.5.15.2. Financial Performance
      • 8.5.15.3. Product Benchmarking
      • 8.5.15.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global breast cancer drugs market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global breast cancer drugs market, by therapy, 2021 - 2033 (USD Million)
  • Table 5 Global breast cancer drugs market, by cancer type, 2021 - 2033 (USD Million)
  • Table 6 Global breast cancer drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 7 North America breast cancer drugs market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America breast cancer drugs market, by therapy, 2021 - 2033 (USD Million)
  • Table 9 North America breast cancer drugs market, by cancer type, 2021 - 2033 (USD Million)
  • Table 10 North America breast cancer drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11 U.S. breast cancer drugs market, by therapy, 2021 - 2033 (USD Million)
  • Table 12 U.S. breast cancer drugs market, by cancer type, 2021 - 2033 (USD Million)
  • Table 13 U.S. breast cancer drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 14 Canada breast cancer drugs market, by therapy, 2021 - 2033 (USD Million)
  • Table 15 Canada breast cancer drugs market, by cancer type, 2021 - 2033 (USD Million)
  • Table 16 Canada breast cancer drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 17 Mexico breast cancer drugs market, by therapy, 2021 - 2033 (USD Million)
  • Table 18 Mexico breast cancer drugs market, by cancer type, 2021 - 2033 (USD Million)
  • Table 19 Mexico breast cancer drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20 Europe breast cancer drugs market, by country, 2021 - 2033 (USD Million)
  • Table 21 Europe breast cancer drugs market, by therapy, 2021 - 2033 (USD Million)
  • Table 22 Europe breast cancer drugs market, by cancer type, 2021 - 2033 (USD Million)
  • Table 23 Europe breast cancer drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24 UK breast cancer drugs market, by therapy, 2021 - 2033 (USD Million)
  • Table 25 UK breast cancer drugs market, by cancer type, 2021 - 2033 (USD Million)
  • Table 26 UK breast cancer drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 27 Germany breast cancer drugs market, by therapy, 2021 - 2033 (USD Million)
  • Table 28 Germany breast cancer drugs market, by cancer type, 2021 - 2033 (USD Million)
  • Table 29 Germany breast cancer drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 France breast cancer drugs market, by therapy, 2021 - 2033 (USD Million)
  • Table 31 France breast cancer drugs market, by cancer type, 2021 - 2033 (USD Million)
  • Table 32 France breast cancer drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 33 Italy breast cancer drugs market, by therapy, 2021 - 2033 (USD Million)
  • Table 34 Italy breast cancer drugs market, by cancer type, 2021 - 2033 (USD Million)
  • Table 35 Italy breast cancer drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 36 Spain breast cancer drugs market, by therapy, 2021 - 2033 (USD Million)
  • Table 37 Spain breast cancer drugs market, by cancer type, 2021 - 2033 (USD Million)
  • Table 38 Spain breast cancer drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39 Norway breast cancer drugs market, by therapy, 2021 - 2033 (USD Million)
  • Table 40 Norway breast cancer drugs market, by cancer type, 2021 - 2033 (USD Million)
  • Table 41 Norway breast cancer drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 42 Denmark breast cancer drugs market, by therapy, 2021 - 2033 (USD Million)
  • Table 43 Denmark breast cancer drugs market, by cancer type, 2021 - 2033 (USD Million)
  • Table 44 Denmark breast cancer drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45 Sweden breast cancer drugs market, by therapy, 2021 - 2033 (USD Million)
  • Table 46 Sweden breast cancer drugs market, by cancer type, 2021 - 2033 (USD Million)
  • Table 47 Sweden breast cancer drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific breast cancer drugs market, by country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific breast cancer drugs market, by therapy, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific breast cancer drugs market, by cancer type, 2021 - 2033(USD
  • Table 51 Asia Pacific breast cancer drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52 Japan breast cancer drugs market, by therapy, 2021 - 2033 (USD Million)
  • Table 53 Japan breast cancer drugs market, by cancer type, 2021 - 2033 (USD Million)
  • Table 54 Japan breast cancer drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 55 China breast cancer drugs market, by therapy, 2021 - 2033 (USD Million)
  • Table 56 China breast cancer drugs market, by cancer type, 2021 - 2033 (USD Million)
  • Table 57 China breast cancer drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 58 India breast cancer drugs market, by therapy, 2021 - 2033 (USD Million)
  • Table 59 India breast cancer drugs market, by cancer type, 2021 - 2033 (USD Million)
  • Table 60 India breast cancer drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61 Australia breast cancer drugs market, by therapy, 2021 - 2033 (USD Million)
  • Table 62 Australia breast cancer drugs market, by cancer type, 2021 - 2033 (USD Million)
  • Table 63 Australia breast cancer drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 64 South Korea breast cancer drugs market, by therapy, 2021 - 2033 (USD Million)
  • Table 65 South Korea breast cancer drugs market, by cancer type, 2021 - 2033 (USD Million)
  • Table 66 South Korea breast cancer drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 67 Thailand breast cancer drugs market, by therapy, 2021 - 2033 (USD Million)
  • Table 68 Thailand breast cancer drugs market, by cancer type, 2021 - 2033 (USD Million)
  • Table 69 Thailand breast cancer drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 70 Latin America breast cancer drugs market, by country, 2021 - 2033 (USD Million)
  • Table 71 Latin America breast cancer drugs market, by therapy, 2021 - 2033 (USD Million)
  • Table 72 Latin America breast cancer drugs market, by cancer type, 2021 - 2033 (USD Million)
  • Table 73 Latin America breast cancer drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 74 Brazil breast cancer drugs market, by therapy, 2021 - 2033 (USD Million)
  • Table 75 Brazil breast cancer drugs market, by cancer type, 2021 - 2033 (USD Million)
  • Table 76 Brazil breast cancer drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 77 Argentina breast cancer drugs market, by therapy, 2021 - 2033 (USD Million)
  • Table 78 Argentina breast cancer drugs market, by cancer type, 2021 - 2033 (USD Million)
  • Table 79 Argentina breast cancer drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 80 Middle East & Africa Breast cancer drugs market, by country, 2021 - 2033 (USD Million)
  • Table 81 Middle East & Africa breast cancer drugs market, by therapy, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa breast cancer drugs market, by cancer type, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa breast cancer drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 84 South Africa breast cancer drugs market, by therapy, 2021 - 2033 (USD Million)
  • Table 85 South Africa breast cancer drugs market, by cancer type, 2021 - 2033 (USD Million)
  • Table 86 South Africa breast cancer drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia breast cancer drugs market, by therapy, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia breast cancer drugs market, by cancer type, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia breast cancer drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 90 UAE breast cancer drugs market, by therapy, 2021 - 2033 (USD Million)
  • Table 91 UAE breast cancer drugs market, by cancer type, 2021 - 2033 (USD Million)
  • Table 92 UAE breast cancer drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 93 Kuwait breast cancer drugs market, by therapy, 2021 - 2033 (USD Million)
  • Table 94 Kuwait breast cancer drugs market, by cancer type, 2021 - 2033 (USD Million)
  • Table 95 Kuwait breast cancer drugs market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Breast cancer drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Breast cancer drugs market dynamics
  • Fig. 11 Breast cancer drugs market: Porter's five forces analysis
  • Fig. 12 Breast cancer drugs market: PESTLE analysis
  • Fig. 13 Therapy market, 2021 - 2033 (USD Million)
  • Fig. 14 Hormonal Therapy market, 2021 - 2033 (USD Million)
  • Fig. 15 Selective Estrogen Receptor Modulators (SERMs) market, 2021 - 2033 (USD Million)
  • Fig. 16 Aromatase Inhibitors market, 2021 - 2033 (USD Million)
  • Fig. 17 Selective Estrogen Receptor Degraders/Down-regulators (SERDs) market, 2021 - 2033 (USD Million)
  • Fig. 18 Targeted Therapy market, 2021 - 2033 (USD Million)
  • Fig. 19 HER2-Targeted Therapies market, 2021 - 2033 (USD Million)
  • Fig. 20 CDK4/6 Inhibitors market, 2021 - 2033 (USD Million)
  • Fig. 21 PARP Inhibitors market, 2021 - 2033 (USD Million)
  • Fig. 22 Antibody-Drug Conjugates (ADCs) market, 2021 - 2033 (USD Million)
  • Fig. 23 Other Targeted Therapies market, 2021 - 2033 (USD Million)
  • Fig. 24 Chemotherapy market, 2021 - 2033 (USD Million)
  • Fig. 25 Taxanes market, 2021 - 2033 (USD Million)
  • Fig. 26 Anthracyclines market, 2021 - 2033 (USD Million)
  • Fig. 27 Others market, 2021 - 2033 (USD Million)
  • Fig. 28 Immunotherapy market, 2021 - 2033 (USD Million)
  • Fig. 29 Cancer Type market, 2021 - 2033 (USD Million)
  • Fig. 30 HR+/HER2- Breast Cancer market, 2021 - 2033 (USD Million)
  • Fig. 31 HER2+ Breast Cancer market, 2021 - 2033 (USD Million)
  • Fig. 32 Triple-Negative Breast Cancer (TNBC / HR-/HER2-) market, 2021 - 2033 (USD Million)
  • Fig. 33 Distribution Channel market, 2021 - 2033 (USD Million)
  • Fig. 34 Hospital Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 35 Retail Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 36 Others market, 2021 - 2033 (USD Million)
  • Fig. 37 Breast cancer drugs market revenue, by region
  • Fig. 38 Regional marketplace: Key takeaways
  • Fig. 39 North America breast cancer drugs market, 2021 - 2033 (USD Million)
  • Fig. 40 U.S. country dynamics
  • Fig. 41 U.S. breast cancer drugs market, 2021 - 2033 (USD Million)
  • Fig. 42 Canada country dynamics
  • Fig. 43 Canada breast cancer drugs market, 2021 - 2033 (USD Million)
  • Fig. 44 Mexico country dynamics
  • Fig. 45 Mexico breast cancer drugs market, 2021 - 2033 (USD Million)
  • Fig. 46 Europe breast cancer drugs market, 2021 - 2033 (USD Million)
  • Fig. 47 UK country dynamics
  • Fig. 48 UK breast cancer drugs market, 2021 - 2033 (USD Million)
  • Fig. 49 Germany country dynamics
  • Fig. 50 Germany breast cancer drugs market, 2021 - 2033 (USD Million)
  • Fig. 51 France country dynamics
  • Fig. 52 France breast cancer drugs market, 2021 - 2033 (USD Million)
  • Fig. 53 Italy country dynamics
  • Fig. 54 Italy breast cancer drugs market, 2021 - 2033 (USD Million)
  • Fig. 55 Spain country dynamics
  • Fig. 56 Spain breast cancer drugs market, 2021 - 2033 (USD Million)
  • Fig. 57 Norway country dynamics
  • Fig. 58 Norway breast cancer drugs market, 2021 - 2033 (USD Million)
  • Fig. 59 Sweden country dynamics
  • Fig. 60 Sweden breast cancer drugs market, 2021 - 2033 (USD Million)
  • Fig. 61 Denmark country dynamics
  • Fig. 62 Denmark breast cancer drugs market, 2021 - 2033 (USD Million)
  • Fig. 63 Asia Pacific breast cancer drugs market, 2021 - 2033 (USD Million)
  • Fig. 64 Japan country dynamics
  • Fig. 65 Japan breast cancer drugs market, 2021 - 2033 (USD Million)
  • Fig. 66 China country dynamics
  • Fig. 67 China breast cancer drugs market, 2021 - 2033 (USD Million)
  • Fig. 68 India country dynamics
  • Fig. 69 India breast cancer drugs market, 2021 - 2033 (USD Million)
  • Fig. 70 Australia country dynamics
  • Fig. 71 Australia breast cancer drugs market, 2021 - 2033 (USD Million)
  • Fig. 72 South Korea country dynamics
  • Fig. 73 South Korea breast cancer drugs market, 2021 - 2033 (USD Million)
  • Fig. 74 Thailand country dynamics
  • Fig. 75 Thailand breast cancer drugs market, 2021 - 2033 (USD Million)
  • Fig. 76 Latin America breast cancer drugs market, 2021 - 2033 (USD Million)
  • Fig. 77 Brazil country dynamics
  • Fig. 78 Brazil breast cancer drugs market, 2021 - 2033 (USD Million)
  • Fig. 79 Argentina country dynamics
  • Fig. 80 Argentina breast cancer drugs market, 2021 - 2033 (USD Million)
  • Fig. 81 MEA breast cancer drugs market, 2021 - 2033 (USD Million)
  • Fig. 82 South Africa country dynamics
  • Fig. 83 South Africa breast cancer drugs market, 2021 - 2033 (USD Million)
  • Fig. 84 Saudi Arabia country dynamics
  • Fig. 85 Saudi Arabia breast cancer drugs market, 2021 - 2033 (USD Million)
  • Fig. 86 UAE country dynamics
  • Fig. 87 UAE breast cancer drugs market, 2021 - 2033 (USD Million)
  • Fig. 88 Kuwait country dynamics
  • Fig. 89 Kuwait breast cancer drugs market, 2021 - 2033 (USD Million)
  • Fig. 90 Company categorization
  • Fig. 91 Company market position analysis
  • Fig. 92 Strategic framework